High-Dose Convalescent Plasma for Treatment of Severe COVID-19.
2019 novel coronavirus disease
Brazil
COVID-19
SARS-CoV-2
convalescent plasma
coronavirus disease
neutralizing antibody
passive immunization
respiratory infections
severe acute respiratory syndrome coronavirus 2
viruses
zoonoses
Journal
Emerging infectious diseases
ISSN: 1080-6059
Titre abrégé: Emerg Infect Dis
Pays: United States
ID NLM: 9508155
Informations de publication
Date de publication:
Mar 2022
Mar 2022
Historique:
pubmed:
27
1
2022
medline:
25
2
2022
entrez:
26
1
2022
Statut:
ppublish
Résumé
To assess whether high-dose coronavirus disease (COVID-19) convalescent plasma (CCP) transfusion may benefit patients with severe COVID-19, we conducted a multicenter randomized trial in Brazil. Patients with severe COVID-19 who were within 10 days of initial symptom onset were eligible. Patients in the CCP group received 3 daily doses of CCP (600 mL/d) in addition to standard treatment; control patients received standard treatment only. Primary outcomes were death rates at days 30 and 60 of study randomization. Secondary outcomes were ventilator-free days and hospital-free days. We enrolled 107 patients: 36 CCP and 71 control. At day 30, death rates were 22% for CCP and 25% for the control group; at day 60, rates were 31% for CCP and 35% for control. Needs for invasive mechanical ventilation and durations of hospital stay were similar between groups. We conclude that high-dose CCP transfused within 10 days of symptom onset provided no benefit for patients with severe COVID-19.
Identifiants
pubmed: 35081022
doi: 10.3201/eid2803.212299
pmc: PMC8888205
doi:
Types de publication
Journal Article
Multicenter Study
Randomized Controlled Trial
Langues
eng
Sous-ensembles de citation
IM
Pagination
548-555Références
Clin Infect Dis. 2011 Feb 15;52(4):447-56
pubmed: 21248066
Radiology. 2020 Apr;295(1):202-207
pubmed: 32017661
Lancet. 2020 Mar 28;395(10229):1054-1062
pubmed: 32171076
Hematology Am Soc Hematol Educ Program. 2018 Nov 30;2018(1):585-594
pubmed: 30570487
Cochrane Database Syst Rev. 2021 May 20;5:CD013600
pubmed: 34013969
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34464358
N Engl J Med. 2021 Feb 18;384(7):619-629
pubmed: 33232588
J Clin Invest. 2021 Jul 1;131(13):
pubmed: 33974559
JAMA. 2020 Apr 28;323(16):1561-1562
pubmed: 32219429
J Clin Invest. 2021 Oct 15;131(20):
pubmed: 34473652
N Engl J Med. 2021 Feb 25;384(8):693-704
pubmed: 32678530
J Clin Invest. 2020 Jun 1;130(6):2757-2765
pubmed: 32254064
Transfusion. 2020 Dec;60(12):2938-2951
pubmed: 32935877
Lancet. 2020 May 16;395(10236):1569-1578
pubmed: 32423584
Eur Respir J. 2022 Feb 10;59(2):
pubmed: 34244316
Lancet. 2021 May 29;397(10289):2049-2059
pubmed: 34000257
Curr Protoc Microbiol. 2020 Jun;57(1):e100
pubmed: 32302069
Antimicrob Agents Chemother. 1994 Aug;38(8):1695-702
pubmed: 7985997
Transfus Med. 2021 Jun 3;:
pubmed: 34085363
JAMA. 2020 Apr 28;323(16):1582-1589
pubmed: 32219428
N Engl J Med. 2021 Mar 18;384(11):1015-1027
pubmed: 33523609
JAMA Netw Open. 2020 Dec 1;3(12):e2029058
pubmed: 33301018
Transfusion. 2021 Aug;61(8):2295-2306
pubmed: 34173248
Science. 2021 Dec 24;374(6575):1586-1593
pubmed: 34726479
Emerg Infect Dis. 2016 Sep;22(9):1554-61
pubmed: 27532807
Nat Med. 2021 Nov;27(11):2012-2024
pubmed: 34504336
Nat Microbiol. 2021 Jan;6(1):11-18
pubmed: 33273742
BMC Infect Dis. 2019 May 2;19(1):376
pubmed: 31046707
Proc Natl Acad Sci U S A. 2020 Apr 28;117(17):9490-9496
pubmed: 32253318
BMJ. 2020 Oct 22;371:m3939
pubmed: 33093056
JAMA. 2020 Aug 4;324(5):460-470
pubmed: 32492084
Clin Immunol. 2021 Jan;222:108634
pubmed: 33217545
N Engl J Med. 2021 Feb 18;384(7):610-618
pubmed: 33406353